Academic Journal
Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial
| العنوان: | Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial |
|---|---|
| المؤلفون: | Li, Jiejie, Meng, Xia, Shi, Fu-Dong, Jing, Jing, Gu, Hong-Qiu, Jin, Aoming, Jiang, Yong, Li, Hao, Johnston, S Claiborne, Hankey, Graeme J, Easton, J Donald, Chang, Liguo, Shi, Penglai, Wang, Lihua, Zhuang, Xianbo, Li, Haitao, Zang, Yingzhuo, Zhang, Jianling, Sun, Zengqiang, Liu, Dongqi, Li, Ying, Yang, Hongqin, Zhao, Jinguo, Yu, Weiran, Wang, Anxin, Pan, Yuesong, Lin, Jinxi, Xie, Xuewei, Jin, Wei-Na, Li, Shuya, Niu, Siying, Wang, Yilong, Zhao, Xingquan, Li, Zixiao, Liu, Liping, Zheng, Huaguang, Wang, Yongjun, on behalf of the CHANCE-3 Investigators |
| بيانات النشر: | BMJ Publishing Group Ltd |
| سنة النشر: | 2024 |
| المجموعة: | HighWire Press (Stanford University) |
| مصطلحات موضوعية: | RESEARCH |
| الوصف: | Objectives To assess the efficacy and safety of colchicine versus placebo on reducing the risk of subsequent stroke after high risk non-cardioembolic ischaemic stroke or transient ischaemic attack within the first three months of symptom onset (CHANCE-3). Design Multicentre, double blind, randomised, placebo controlled trial. Setting 244 hospitals in China between 11 August 2022 and 13 April 2023. Participants 8343 patients aged 40 years of age or older with a minor-to-moderate ischaemic stroke or transient ischaemic attack and a high sensitivity C-reactive protein ≥2 mg/L were enrolled. Interventions Patients were randomly assigned 1:1 within 24 h of symptom onset to receive colchicine (0.5 mg twice daily on days 1-3, followed by 0.5 mg daily thereafter) or placebo for 90 days. Main outcome measures The primary efficacy outcome was any new stroke within 90 days after randomisation. The primary safety outcome was any serious adverse event during the treatment period. All efficacy and safety analyses were by intention to treat. Results 4176 patients were assigned to the colchicine group and 4167 were assigned to the placebo group. Stroke occurred within 90 days in 264 patients (6.3%) in the colchicine group and 270 patients (6.5%) in the placebo group (hazard ratio 0.98 (95% confidence interval 0.83 to 1.16); P=0.79). Any serious adverse event was observed in 91 (2.2%) patients in the colchicine group and 88 (2.1%) in the placebo group (P=0.83). Conclusions The study did not provide evidence that low-dose colchicine could reduce the risk of subsequent stroke within 90 days as compared with placebo among patients with acute non-cardioembolic minor-to-moderate ischaemic stroke or transient ischaemic attack and a high sensitivity C-reactive protein ≥2 mg/L. Trial registration ClinicalTrials.gov, NCT05439356 . |
| نوع الوثيقة: | text |
| وصف الملف: | text/html |
| اللغة: | English |
| Relation: | http://www.bmj.com/cgi/content/short/385/jun26_3/e079061; http://dx.doi.org/10.1136/bmj-2023-079061 |
| DOI: | 10.1136/bmj-2023-079061 |
| الاتاحة: | http://www.bmj.com/cgi/content/short/385/jun26_3/e079061 https://doi.org/10.1136/bmj-2023-079061 |
| Rights: | Copyright (C) 2024, BMJ Publishing Group Ltd |
| رقم الانضمام: | edsbas.F89714C6 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1136/bmj-2023-079061 |
|---|